Real-time Estimate
Cboe BZX
12:17:16 2024-06-10 pm EDT
|
5-day change
|
1st Jan Change
|
1.315
USD
|
-2.59%
|
|
-8.68%
|
-30.42%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
275.4
|
684.6
|
383.1
|
81.58
|
110.9
|
-
|
-
|
Enterprise Value (EV)
1 |
275.4
|
684.6
|
383.1
|
81.58
|
110.9
|
110.9
|
110.9
|
P/E ratio
|
-2.8
x
|
-8.75
x
|
-5.26
x
|
-0.57
x
|
-0.83
x
|
-0.85
x
|
-0.77
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
15.4
x
|
70.4
x
|
15.3
x
|
-
|
66.6
x
|
35.5
x
|
26.6
x
|
EV / Revenue
|
15.4
x
|
70.4
x
|
15.3
x
|
-
|
66.6
x
|
35.5
x
|
26.6
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-10.8
x
|
-
|
-0.83
x
|
-1.38
x
|
-1.23
x
|
-1.16
x
|
FCF Yield
|
-
|
-9.29%
|
-
|
-120%
|
-72.5%
|
-81.5%
|
-86.4%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
19,601
|
39,143
|
42,851
|
43,165
|
82,174
|
-
|
-
|
Reference price
2 |
14.05
|
17.49
|
8.940
|
1.890
|
1.350
|
1.350
|
1.350
|
Announcement Date
|
3/11/21
|
3/15/22
|
3/15/23
|
3/19/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
17.9
|
9.73
|
24.99
|
-
|
1.667
|
3.125
|
4.167
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-39.19
|
-61.43
|
-72.55
|
-152
|
-127.1
|
-130.4
|
-142.3
|
Operating Margin
|
-218.91%
|
-631.38%
|
-290.32%
|
-
|
-7,625.2%
|
-4,173.68%
|
-3,414.74%
|
Earnings before Tax (EBT)
1 |
-39.49
|
-62.12
|
-69.79
|
-142.7
|
-118.5
|
-125.5
|
-136.2
|
Net income
1 |
-36.68
|
-62
|
-69.79
|
-142.7
|
-118.5
|
-125.5
|
-136.2
|
Net margin
|
-204.87%
|
-637.19%
|
-279.27%
|
-
|
-7,112.46%
|
-4,015.28%
|
-3,269.09%
|
EPS
2 |
-5.010
|
-2.000
|
-1.700
|
-3.310
|
-1.624
|
-1.583
|
-1.760
|
Free Cash Flow
1 |
-
|
-63.59
|
-
|
-98.18
|
-80.4
|
-90.45
|
-95.8
|
FCF margin
|
-
|
-653.51%
|
-
|
-
|
-4,823.99%
|
-2,894.4%
|
-2,299.2%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/11/21
|
3/15/22
|
3/15/23
|
3/19/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
5.468
|
24.99
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
0.5556
|
0.5556
|
0.5556
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-15.54
|
4.706
|
-22.71
|
-22.98
|
-31.56
|
-33.32
|
-34.89
|
-52.26
|
-31.57
|
-30.87
|
-31.42
|
-31.72
|
-33.07
|
-34.36
|
-35.04
|
Operating Margin
|
-284.24%
|
18.83%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-5,654.97%
|
-5,709.78%
|
-5,952.93%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-15.82
|
4.618
|
-22.54
|
-22
|
-29.88
|
-30.88
|
-32.4
|
-49.88
|
-29.49
|
-28.02
|
-29.37
|
-29.79
|
-31.32
|
-33.96
|
-34.69
|
Net income
1 |
-15.81
|
4.618
|
-22.54
|
-22
|
-29.88
|
-30.88
|
-32.4
|
-49.88
|
-29.49
|
-28.02
|
-29.37
|
-29.79
|
-31.32
|
-33.96
|
-34.69
|
Net margin
|
-289.19%
|
18.48%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-5,286.78%
|
-5,362.52%
|
-5,636.65%
|
-
|
-
|
EPS
2 |
-0.4700
|
0.1000
|
-0.5600
|
-0.5300
|
-0.7200
|
-0.7200
|
-0.7500
|
-1.160
|
-0.6900
|
-0.3500
|
-0.3633
|
-0.3667
|
-0.3822
|
-0.3833
|
-0.3267
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/15/22
|
5/12/22
|
8/10/22
|
11/8/22
|
3/15/23
|
5/9/23
|
8/9/23
|
11/8/23
|
3/19/24
|
5/14/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-63.6
|
-
|
-98.2
|
-80.4
|
-90.5
|
-95.8
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-23.4%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-20.8%
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
334.8
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
13
|
-
|
4.46
|
3.28
|
5.13
|
3.86
|
Capex / Sales
|
-
|
134.08%
|
-
|
-
|
196.65%
|
164.24%
|
92.74%
|
Announcement Date
|
3/11/21
|
3/15/22
|
3/15/23
|
3/19/24
|
-
|
-
|
-
|
Last Close Price
1.35
USD Average target price
9
USD Spread / Average Target +566.67% Consensus |
1st Jan change
|
Capi.
|
---|
| -30.42% | 111M | | +48.07% | 57.87B | | +41.65% | 40.25B | | -7.02% | 39.94B | | -5.96% | 28.54B | | +12.14% | 26.4B | | -20.70% | 19.33B | | +30.11% | 12.4B | | -0.82% | 12.23B | | +24.43% | 12.2B |
Other Biotechnology & Medical Research
|